Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03280667
Title Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Indications

renal cell carcinoma

Therapies

Denosumab + Pembrolizumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.